My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 85

    1.

    Treatment escalation and rise in HbA1c following successful initial metformin therapy.

    Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl SJ, Brown JB.

    Diabetes Care. 2006 Mar;29(3):504-9.PMID: 16505496 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Contemporary analysis of secondary failure of successful sulfonylurea therapy.

    Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl SJ, Brown JB.

    Endocr Pract. 2007 Jan-Feb;13(1):37-44.PMID: 17360299 [PubMed - indexed for MEDLINE]Related articles

    3.

    Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy.

    Riedel AA, Heien H, Wogen J, Plauschinat CA.

    Pharmacotherapy. 2007 Aug;27(8):1102-10.PMID: 17655510 [PubMed - indexed for MEDLINE]Related articles

    4.

    Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen.

    Riedel AA, Heien H, Wogen J, Plauschinat CA.

    Am J Manag Care. 2007 Aug;13(8):457-63.PMID: 17685826 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes.

    Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR.

    Diabetes Care. 2005 May;28(5):995-1000.PMID: 15855556 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program.

    Lawrence DB, Ragucci KR, Long LB, Parris BS, Helfer LA.

    J Manag Care Pharm. 2006 Jul-Aug;12(6):466-71.PMID: 16925454 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care.

    Cook MN, Girman CJ, Stein PP, Alexander CM.

    Diabet Med. 2007 Apr;24(4):350-8. Epub 2007 Feb 28.PMID: 17335466 [PubMed - indexed for MEDLINE]Related articles

    8.

    Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study.

    Zhou K, Donnelly LA, Kimber CH, Donnan PT, Doney AS, Leese G, Hattersley AT, McCarthy MI, Morris AD, Palmer CN, Pearson ER.

    Diabetes. 2009 Jun;58(6):1434-9. Epub 2009 Mar 31.PMID: 19336679 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.

    Lewin A, Lipetz R, Wu J, Schwartz S.

    Clin Ther. 2007 May;29(5):844-55.PMID: 17697903 [PubMed - indexed for MEDLINE]Related articles

    10.

    An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea.

    Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M.

    Diabetes Care. 2006 Jun;29(6):1282-7.PMID: 16732009 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

    Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group.

    Diabetes Care. 2006 Dec;29(12):2638-43.PMID: 17130197 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.

    Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME.

    Clin Ther. 2007 Nov;29(11):2333-48.PMID: 18158075 [PubMed - indexed for MEDLINE]Related articles

    13.

    Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

    Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

    14.

    Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

    Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

    Diabetes Care. 2006 Mar;29(3):554-9.PMID: 16505505 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus.

    Eurich DT, Simpson SH, Majumdar SR, Johnson JA.

    Pharmacotherapy. 2005 Jun;25(6):810-6.PMID: 15927899 [PubMed - indexed for MEDLINE]Related articles

    16.

    Glycemic response to newly initiated diabetes therapies.

    Karter AJ, Moffet HH, Liu J, Parker MM, Ahmed AT, Go AS, Selby JV.

    Am J Manag Care. 2007 Nov;13(11):598-606.PMID: 17988185 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study.

    Yurgin N, Secnik K, Lage MJ.

    Clin Ther. 2007 Feb;29(2):316-25.PMID: 17472823 [PubMed - indexed for MEDLINE]Related articles

    18.

    Haemoglobin A1c goal attainment in relation to dose in patients with diabetes mellitus taking metformin: a nested, case-control study.

    Penning-van Beest FJ, Wolffenbuttel BH, Herings RM.

    Clin Drug Investig. 2008;28(8):487-93.PMID: 18598094 [PubMed - indexed for MEDLINE]Related articles

    19.

    Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1C less than 7%.

    Pani LN, Nathan DM, Grant RW.

    Diabetes Care. 2008 Mar;31(3):386-90. Epub 2007 Dec 14.PMID: 18083790 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Metformin as secondary therapy in a defined population with type 2 diabetes.

    Brown JB, Pedula KL.

    Clin Ther. 1999 Oct;21(10):1678-87.PMID: 10566564 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity